ABCL · AbCellera Biologics Inc. · Webcasts, Transcripts & Audio
$11.02
-0.01 (-0.09%)
At close · Nov 18
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$3.60B
Shares
326.62M
Volume · Nov 18
2.59M
Avg daily vol (3M)
4.51M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
AbCellera Biologics Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for AbCellera Biologics Inc. (ABCL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
AbCellera Biologics Inc. (ABCL) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
AbCellera Biologics Inc. (ABCL) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
AbCellera Biologics Inc. (ABCL) November 16, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-11
AbCellera Biologics Inc. (ABCL) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-09
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
Confident tone
Late-stage ABCL635 development
ABCL635 efficacy
Additional VMS indications
Revenue
$10.64M
▲ 18.8% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
Positive tone
Business development deals (Vertex, Jazz, AbbVie)
T-cell engagement (TCE) platform and partnerships
ABCL635 Phase 2 in VMS/menopause
Revenue
$4.05M
▼ 76.3% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
AbCellera Biologics Inc. (ABCL) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
AbCellera Biologics Inc. (ABCL) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-11
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
Confident tone
ABCL 635 Phase II readout
Dosing strategy and PK/PD
Pipeline priorities and catalysts
Revenue
$8.31M
▲ 96.3% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-21
AbCellera Biologics Inc. (ABCL) April 21, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
Confident tone
Pipeline expansion and development candidates
Liquidity and financial position
ABCL635 Phase II readout
Revenue
$44.85M*
▲ 788.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript
Positive tone
Liquidity and financial position
Partner-initiated programs
Clinical pipeline progress
Revenue
$8.96M
▲ 37.6% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript
Confident tone
ABCL575 atopic dermatitis program
ABCL635 vasomotor symptoms program
Revenue and partner programs
Revenue
$17.08M
▲ 133.3% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript
Positive tone
ABCL635 program (NK3R antibody for menopausal VMS)
Clinical milestones and timing
Differentiation vs. small molecule NK3R antagonists
Revenue
$4.24M
▼ 57.5% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
Positive tone
Facilities and platform investments
Reduced partnership activity
Tariffs and macro headwinds
Revenue
$5.05M*
▼ 45% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript
Positive tone
Liquidity and cash runway
Platform and facility build-out
Partnering strategy shift to co-development
Revenue
$6.51M
▼ 1.4% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
AbCellera Biologics Inc. (ABCL) Q2 2024 Earnings Call Transcript
Positive tone
TCE platform programs
Strategic partnerships and business development
Revenue and financial trends
Revenue
$7.32M
▼ 27.2% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript
Positive tone
TCE platform and technology
Strategic partnerships and deal-making
Internal pipeline advancement
Revenue
$9.95M
▼ 18.4% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript
Confident tone
Internal programs ABCL635 and ABCL575 progress
Manufacturing build-out and forward integration
Partnerships and royalty portfolio
Revenue
$9.18M*
▼ 57.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript
Revenue
$6.60M
▼ 93.5% YoY Diluted EPS
$-0.10
▼ 225% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript
Revenue
$10.06M
▼ 78.1% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript
Revenue
$12.19M
▼ 96.1% YoY Diluted EPS
$-0.14
▼ 125.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
AbCellera Biologics Inc. (ABCL) Q4 2022 Earnings Call Transcript
Revenue
$21.54M*
▼ 84.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript
Revenue
$101.38M
▲ 1740.6% YoY Diluted EPS
$0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
AbCellera Biologics Inc. (ABCL) Q2 2022 Earnings Call Transcript
Revenue
$45.92M
▲ 66.1% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
AbCellera Biologics Inc. (ABCL) Q1 2022 Earnings Call Transcript
Revenue
$316.58M
▲ 56.2% YoY Diluted EPS
$0.54
▲ 45.9% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
AbCellera Biologics Inc. (ABCL) Q4 2021 Earnings Call Transcript
Revenue
$139.31M*
▼ 33% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript
Revenue
$5.51M
▼ 41.2% YoY Diluted EPS
$-0.08
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript
Revenue
$27.64M
▲ 146.2% YoY Diluted EPS
$-0.01
▼ 133.3% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
AbCellera Biologics Inc. (ABCL) Q1 2021 Earnings Call Transcript
Revenue
$202.74M
▲ 4253.5% YoY Diluted EPS
$0.37
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-29
AbCellera Biologics Inc. (ABCL) Q4 2020 Earnings Call Transcript
Revenue
$207.91M*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 webcasts
Key facts
CIK
1703057
CUSIP
00288U106
13F (30d)
172 filings
162 filers
Visit website
Investor relations